IL293330A - mhc ii peptide protein structures and uses thereof - Google Patents

mhc ii peptide protein structures and uses thereof

Info

Publication number
IL293330A
IL293330A IL293330A IL29333022A IL293330A IL 293330 A IL293330 A IL 293330A IL 293330 A IL293330 A IL 293330A IL 29333022 A IL29333022 A IL 29333022A IL 293330 A IL293330 A IL 293330A
Authority
IL
Israel
Prior art keywords
mhc class
chain
mhc
peptide
composition
Prior art date
Application number
IL293330A
Other languages
English (en)
Hebrew (he)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL293330A publication Critical patent/IL293330A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL293330A 2019-12-02 2020-12-02 mhc ii peptide protein structures and uses thereof IL293330A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962942344P 2019-12-02 2019-12-02
PCT/US2020/062801 WO2021113297A1 (en) 2019-12-02 2020-12-02 Peptide-mhc ii protein constructs and uses thereof

Publications (1)

Publication Number Publication Date
IL293330A true IL293330A (en) 2022-07-01

Family

ID=74046157

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293330A IL293330A (en) 2019-12-02 2020-12-02 mhc ii peptide protein structures and uses thereof

Country Status (9)

Country Link
US (1) US20220409732A1 (2)
EP (1) EP4069722A1 (2)
JP (2) JP7726881B2 (2)
KR (1) KR20220110233A (2)
CN (1) CN114901678A (2)
AU (1) AU2020395122A1 (2)
CA (1) CA3163549A1 (2)
IL (1) IL293330A (2)
WO (1) WO2021113297A1 (2)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
JP2026507123A (ja) 2023-02-28 2026-02-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔ細胞活性化剤およびその使用方法
CN118813436A (zh) * 2023-07-24 2024-10-22 佳吾益(北京)科技有限公司 展示单mhc等位基因功能蛋白的工程化细胞
WO2025064770A2 (en) * 2023-09-20 2025-03-27 La Jolla Institute of Immunology Alphavirus t cell epitopes, megapools and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025064029A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibody molecules binding to a peptide-mhc interface
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2026006724A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Prame off-target peptides and uses thereof
WO2026006734A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002076196A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transgenic animals expressing antibodies specific for genes of interest and uses thereof
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
PL2602323T3 (pl) 2007-06-01 2018-06-29 Open Monoclonal Technology, Inc. Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego
EP2147594B1 (en) 2008-06-27 2013-11-13 Merus B.V. Antibody producing non-human mammals
AU2009298458B2 (en) 2008-09-30 2015-10-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
DK3622815T3 (da) 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
ES2724975T3 (es) 2009-12-10 2019-09-18 Regeneron Pharma Ratones que producen anticuerpos de cadena pesada
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
GB201002730D0 (en) * 2010-02-18 2010-04-07 Uni I Oslo Product
ES2984483T3 (es) 2010-03-31 2024-10-29 Ablexis Llc Ingeniería genética de ratones para la producción de anticuerpos quiméricos
WO2011147894A1 (en) * 2010-05-25 2011-12-01 Forschungsverbund Berlin E.V. Chimeric mhc class ii proteinpeptide
PT3034608T (pt) 2010-06-22 2019-05-28 Regeneron Pharma Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
JP2012120488A (ja) 2010-12-09 2012-06-28 Univ Of Tokyo 新規安定化組換えｍｈｃタンパク質
ME02106B (me) 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
SG11201401181YA (en) 2011-10-17 2014-04-28 Regeneron Pharma Restricted immunoglobulin heavy chain mice
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
SMT202200205T1 (it) 2011-10-28 2022-07-21 Regeneron Pharma Topi geneticamente modificati che esprimono molecole chimeriche del complesso maggiore di istocompatibilità (mhc) ii
CN107858333B (zh) 2011-10-28 2022-05-27 瑞泽恩制药公司 T细胞受体基因修饰小鼠
JP6364352B2 (ja) 2012-01-06 2018-07-25 オレゴン ヘルス アンド サイエンス ユニバーシティ 部分的ｍｈｃコンストラクト及びその使用方法
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
PT2931030T (pt) 2012-12-14 2020-08-03 Open Monoclonal Tech Inc Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem
US9475559B2 (en) 2013-07-03 2016-10-25 Hobie Cat Company Foot operated propulsion system for watercraft
US9410301B2 (en) 2014-12-09 2016-08-09 Theophile Bourgeois Patch system and method for oil boom
CN113831407B (zh) 2016-05-20 2024-06-11 瑞泽恩制药公司 用于使用多个引导rna来破坏免疫耐受性的方法
US20180127481A1 (en) 2016-11-09 2018-05-10 Uti Limited Partnership RECOMBINANT pMHC CLASS II MOLECULES
WO2019051126A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF
CN117777294A (zh) * 2017-10-03 2024-03-29 中外制药株式会社 抗hla-dq2.5抗体
RU2763798C1 (ru) * 2017-12-23 2022-01-11 Рубиус Терапьютикс, Инк. Искусственные антигенпрезентирующие клетки и способы их применения
EP3772927B1 (en) 2018-03-24 2025-01-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof

Also Published As

Publication number Publication date
AU2020395122A1 (en) 2022-06-09
KR20220110233A (ko) 2022-08-05
US20220409732A1 (en) 2022-12-29
WO2021113297A1 (en) 2021-06-10
EP4069722A1 (en) 2022-10-12
JP2025159063A (ja) 2025-10-17
JP2023504172A (ja) 2023-02-01
JP7726881B2 (ja) 2025-08-20
CN114901678A (zh) 2022-08-12
CA3163549A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
JP7726881B2 (ja) ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
US20250304652A1 (en) Half-life extended immtac binding cd3 and a hla-a*02 restricted peptide
KR102862947B1 (ko) 펩티드-mhc 복합체에 대한 치료 항체를 생성하기 위한 유전적으로 변형된 비인간 동물, 이의 제조 방법
JP6538622B2 (ja) ホモ二量体タンパク質コンストラクト
JP2021500855A (ja) 抗原提示ポリペプチドおよびその使用方法
WO1996013593A2 (en) Soluble single chain t cell receptors
KR20260021695A (ko) 이기능성 결합 폴리펩타이드
JP2022522404A (ja) Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
AU2022263441A9 (en) Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof
US20250057966A1 (en) Single chain constructs
US20250270284A1 (en) MHC Class II Protein Constructs
US20240181025A1 (en) Antigen Presenting Polypeptide Complexes Bearing TGF-Beta and Methods of Use Thereof
KR20210071019A (ko) 변형된 MHC 클래스 II DRα1 도메인을 포함하는 재조합 폴리펩타이드 및 이의 사용 방법
RU2833530C2 (ru) Молекулы immtac, связывающие рестриктированный по hla-a*02 пептид, с увеличенным периодом полувыведения
WO2025111562A1 (en) Mhc class ii protein complexes
MacNeil Regulation of T cell responses by peptides of the T cell receptor ̀chain variable region
WO1995015977A1 (en) Peptide representing antigenic epitopes of feline ige present on feline b-cells but not feline basophil cell surfaces
JP2019033762A (ja) ホモ二量体タンパク質コンストラクト
HK1089452A (en) Modified soluble t cell receptor